clinical trial · NCT06980116
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.·phase1·recruiting·n = 50
Relapsed or Refractory B-cell MalignanciesEXS73565
brief summary
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of EXS73565 administered orally as a single agent in participants with relapsed/refractory B-cell malignancies.
started
Mar 31, 2025
primary completion
Jun 1, 2028
completion
Dec 1, 2028
last updated
Dec 3, 2025
official title
A Phase 1 Open-label, Multicenter, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of EXS73565 in Participants With Relapsed or Refractory B-cell Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol